Usefulness of Multisite Ventricular Pacing in Nonresponders to Cardiac Resynchronization Therapy.

Cardiac resynchronization therapy (CRT) is an established treatment for heart failure patients with myocardial dysfunction and delayed ventricular activation, but approximately 25% to 40% of patients do not respond to CRT. Left ventricular (LV) multisite pacing (MSP) has been proposed as a tool to improve CRT response. The goal of this study is to examine the safety and efficacy of LV MSP in CRT nonresponders. Between January 2018, and September 2019, the Strategic Management to Improve CRT Using Multi-Site Pacing trial prospectively enrolled 584 CRT-defibrillator recipients for established indications at 52 sites across the United States and evaluated their response at 6 months using the clinical composite score (CCS). Of the nonresponders, 102 patients had the LV MSP feature turned on and 78 patients completed the 12-month CCS evaluation. The LV MSP feature-related complication-free rate was 99.0% with a lower 95% confidence interval limit of 94.9%, which was higher than the performance goal of 90%. The proportion of nonresponders with an improved CCS from 6 to 12 months was 51.3% with a lower 95% confidence interval limit of 41.4%, which was higher than the performance goal of 5%. The estimated mean reduction in battery longevity with the LV MSP feature was about 3.6 months (estimated battery longevity of 8.87 ± 2.08 years at 6 months and 8.07 ± 2.23 years at 12 months). In conclusion, in CRT nonresponders, the use of the LV MSP feature is safe and associated with a ∼50% conversion rate with a small projected reduction in CRT-defibrillator battery longevity. LV MSP should be considered in the management of CRT nonresponders.

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosures Dr. Saba has received research support from Abbott and Boston Scientific and reports receiving consultation payments from Boston Scientific and Medtronic. Dr. Nair reports receiving research support, consultation, advisory board, education and training fees from Abbott, Boston Scientific, Medtronic (Abbott), and Adagio, and advisory board fees from Biosense Webster. Dr. Ellis reports receiving research support from Boehringer-Ingelheim, Medtronic, Boston Scientific, and Consulting/Advisory Board payments from Medtronic, Boston Scientific. Dr. Winner reports receiving consultation fees from Boston Scientific and Speaker fees from Medtronic. Dr. Jain reports receiving research support from Medtronic and Boston Scientific. Dr. Ellenbogen reports receiving research support from Medtronic and Boston Scientific, consultation fees from Abbott, and honoraria for lectures from Boston Scientific and Medtronic. Three authors (SM, TS, and KS) are employees of Boston Scientific. The other authors have no conflicts of interest to declare.